OBJECTIVE: To measure progress in implementing co-trimoxazole prophylaxis (CTXp) (trimethoprim plus sulfamethoxazole) and isoniazid preventive therapy (IPT) policy recommendations, identify barriers to the development of national policies and pinpoint challenges to implementation. METHODS: In 2007 we conducted by e-mail a cross-sectional survey of World Health Organization (WHO) HIV/AIDS programme officers in 69 selected countries having a high burden of infection with HIV or HIV-associated tuberculosis (TB). The specially-designed, self-administered questionnaire contained items covering national policies for CTXp and IPT in people living with HIV, current level of implementation and barriers to developing or implementing these policies. FINDINGS: The 41 (59%) respondent countries, representing all WHO regions, comprised 85% of the global burden of HIV-associated TB and 82% of the global burden of HIV infection. Thirty-eight countries (93%) had an established national policy for CTXp, but only 66% of them (25/38) had achieved nationwide implementation. For IPT, 21 of 41 countries (51%) had a national policy but only 28% of them (6/21) had achieved nationwide implementation. Despite significant progress in the development of CTXp policy, the limited availability of co-trimoxazole for this indication and inadequate systems to manage drug supply impeded nationwide implementation. Inadequate intensified tuberculosis case-finding and concerns regarding isoniazid resistance were challenges to the development and implementation of national IPT policies. CONCLUSION: Despite progress in implementing WHO-recommended CTXp and IPT policies, these interventions remain underused. Urgent steps are required to facilitate the development and implementation of these policies.
OBJECTIVE: To measure progress in implementing co-trimoxazole prophylaxis (CTXp) (trimethoprim plus sulfamethoxazole) and isoniazid preventive therapy (IPT) policy recommendations, identify barriers to the development of national policies and pinpoint challenges to implementation. METHODS: In 2007 we conducted by e-mail a cross-sectional survey of World Health Organization (WHO) HIV/AIDS programme officers in 69 selected countries having a high burden of infection with HIV or HIV-associated tuberculosis (TB). The specially-designed, self-administered questionnaire contained items covering national policies for CTXp and IPT in people living with HIV, current level of implementation and barriers to developing or implementing these policies. FINDINGS: The 41 (59%) respondent countries, representing all WHO regions, comprised 85% of the global burden of HIV-associated TB and 82% of the global burden of HIV infection. Thirty-eight countries (93%) had an established national policy for CTXp, but only 66% of them (25/38) had achieved nationwide implementation. For IPT, 21 of 41 countries (51%) had a national policy but only 28% of them (6/21) had achieved nationwide implementation. Despite significant progress in the development of CTXp policy, the limited availability of co-trimoxazole for this indication and inadequate systems to manage drug supply impeded nationwide implementation. Inadequate intensified tuberculosis case-finding and concerns regarding isoniazid resistance were challenges to the development and implementation of national IPT policies. CONCLUSION: Despite progress in implementing WHO-recommended CTXp and IPT policies, these interventions remain underused. Urgent steps are required to facilitate the development and implementation of these policies.
Authors: Sue J Goldie; Yazdan Yazdanpanah; Elena Losina; Milton C Weinstein; Xavier Anglaret; Rochelle P Walensky; Heather E Hsu; April Kimmel; Charles Holmes; Jonathan E Kaplan; Kenneth A Freedberg Journal: N Engl J Med Date: 2006-09-14 Impact factor: 91.245
Authors: X Anglaret; G Chêne; A Attia; S Toure; S Lafont; P Combe; K Manlan; T N'Dri-Yoman; R Salamon Journal: Lancet Date: 1999-05-01 Impact factor: 79.321
Authors: C Chintu; G J Bhat; A S Walker; V Mulenga; F Sinyinza; K Lishimpi; L Farrelly; N Kaganson; A Zumla; S H Gillespie; A J Nunn; D M Gibb Journal: Lancet Date: 2004 Nov 20-26 Impact factor: 79.321
Authors: Jonathan E Golub; Valeria Saraceni; Solange C Cavalcante; Antonio G Pacheco; Lawrence H Moulton; Bonnie S King; Anne Efron; Richard D Moore; Richard E Chaisson; Betina Durovni Journal: AIDS Date: 2007-07-11 Impact factor: 4.177
Authors: Christine Watera; Jim Todd; Richard Muwonge; James Whitworth; Jessica Nakiyingi-Miiro; Anne Brink; George Miiro; Lucy Antvelink; Anatoli Kamali; Neil French; Jonathan Mermin Journal: J Acquir Immune Defic Syndr Date: 2006-07 Impact factor: 3.731
Authors: Veronica Mulenga; Deborah Ford; A Sarah Walker; Darlington Mwenya; James Mwansa; Frederick Sinyinza; Kennedy Lishimpi; Andrew Nunn; Stephen Gillespie; Ali Zumla; Chifumbe Chintu; Diana M Gibb Journal: AIDS Date: 2007-01-02 Impact factor: 4.177
Authors: Paula Braitstein; Martin W G Brinkhof; François Dabis; Mauro Schechter; Andrew Boulle; Paolo Miotti; Robin Wood; Christian Laurent; Eduardo Sprinz; Catherine Seyler; David R Bangsberg; Eric Balestre; Jonathan A C Sterne; Margaret May; Matthias Egger Journal: Lancet Date: 2006-03-11 Impact factor: 79.321
Authors: Sam Ogwang; Hoa T Nguyen; Marissa Sherman; Saralee Bajaksouzian; Michael R Jacobs; W Henry Boom; Guo-Fang Zhang; Liem Nguyen Journal: J Biol Chem Date: 2011-03-03 Impact factor: 5.157
Authors: Valeria Saraceni; Silvia Cohn; Solange C Cavalcante; Antonio G F Pacheco; Lawrence H Moulton; Richard E Chaisson; Betina Durovni; Jonathan E Golub Journal: J Acquir Immune Defic Syndr Date: 2014-09-01 Impact factor: 3.731
Authors: Nyanyiwe M Mbeye; Feiko O ter Kuile; Mary-Ann Davies; Kamija S Phiri; Matthias Egger; Gilles Wandeler Journal: Trop Med Int Health Date: 2014-07-08 Impact factor: 2.622